Surmodics, Inc. (SRDX) Stock Competitors & Peer Comparison
See (SRDX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRDX | $42.98 | +0.00% | 614.5M | -34.66 | -$1.24 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $90.78 | +4.36% | 158B | 25.41 | $3.57 | +2.71% |
| ISRG | $418.82 | +2.83% | 148.4B | 50.78 | $8.25 | N/A |
| SYK | $301.21 | +2.11% | 115.4B | 34.81 | $8.65 | +1.15% |
| MDT | $81.93 | +5.11% | 105.2B | 21.97 | $3.73 | +3.49% |
| BSX | $48.85 | +2.43% | 72.6B | 20.43 | $2.39 | N/A |
| BRKRP | $460.67 | -0.63% | 67.4B | N/A | N/A | +0.33% |
| EW | $87.45 | +1.69% | 50.3B | 47.26 | $1.85 | N/A |
| RMD | $194.32 | +4.22% | 28.2B | 18.74 | $10.37 | +1.25% |
Stock Comparison
SRDX vs BSX-PA Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SRDX is priced at $42.98, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SRDX's ROE is -0.13%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSX-PA's competition here
SRDX vs ABT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABT has a market cap of 158B. Regarding current trading prices, SRDX is priced at $42.98, while ABT trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABT's P/E ratio is 25.41. In terms of profitability, SRDX's ROE is -0.13%, compared to ABT's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ABT's competition here
SRDX vs ISRG Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ISRG has a market cap of 148.4B. Regarding current trading prices, SRDX is priced at $42.98, while ISRG trades at $418.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ISRG's P/E ratio is 50.78. In terms of profitability, SRDX's ROE is -0.13%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, SRDX is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ISRG's competition here
SRDX vs SYK Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, SRDX is priced at $42.98, while SYK trades at $301.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SYK's P/E ratio is 34.81. In terms of profitability, SRDX's ROE is -0.13%, compared to SYK's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SYK's competition here
SRDX vs MDT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, SRDX is priced at $42.98, while MDT trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDT's P/E ratio is 21.97. In terms of profitability, SRDX's ROE is -0.13%, compared to MDT's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MDT's competition here
SRDX vs BSX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX has a market cap of 72.6B. Regarding current trading prices, SRDX is priced at $42.98, while BSX trades at $48.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX's P/E ratio is 20.43. In terms of profitability, SRDX's ROE is -0.13%, compared to BSX's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSX's competition here
SRDX vs BRKRP Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKRP has a market cap of 67.4B. Regarding current trading prices, SRDX is priced at $42.98, while BRKRP trades at $460.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKRP's P/E ratio is N/A. In terms of profitability, SRDX's ROE is -0.13%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, SRDX and BRKRP have similar daily volatility (0.00).Check BRKRP's competition here
SRDX vs EW Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, SRDX is priced at $42.98, while EW trades at $87.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EW's P/E ratio is 47.26. In terms of profitability, SRDX's ROE is -0.13%, compared to EW's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EW's competition here
SRDX vs RMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, SRDX is priced at $42.98, while RMD trades at $194.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RMD's P/E ratio is 18.74. In terms of profitability, SRDX's ROE is -0.13%, compared to RMD's ROE of +0.24%. Regarding short-term risk, SRDX is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check RMD's competition here
SRDX vs DXCM Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DXCM has a market cap of 28B. Regarding current trading prices, SRDX is priced at $42.98, while DXCM trades at $72.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DXCM's P/E ratio is 31.15. In terms of profitability, SRDX's ROE is -0.13%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, SRDX is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check DXCM's competition here
SRDX vs PHG Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, SRDX is priced at $42.98, while PHG trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PHG's P/E ratio is 22.40. In terms of profitability, SRDX's ROE is -0.13%, compared to PHG's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PHG's competition here
SRDX vs STE Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, SRDX is priced at $42.98, while STE trades at $212.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas STE's P/E ratio is 26.76. In terms of profitability, SRDX's ROE is -0.13%, compared to STE's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check STE's competition here
SRDX vs ABMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SRDX is priced at $42.98, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SRDX's ROE is -0.13%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ABMD's competition here
SRDX vs ZBH Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZBH has a market cap of 16.8B. Regarding current trading prices, SRDX is priced at $42.98, while ZBH trades at $86.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZBH's P/E ratio is 22.46. In terms of profitability, SRDX's ROE is -0.13%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SRDX is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ZBH's competition here
SRDX vs SNN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, SRDX is priced at $42.98, while SNN trades at $30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SNN's P/E ratio is 21.57. In terms of profitability, SRDX's ROE is -0.13%, compared to SNN's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SNN's competition here
SRDX vs PEN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, SRDX is priced at $42.98, while PEN trades at $320.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PEN's P/E ratio is 74.06. In terms of profitability, SRDX's ROE is -0.13%, compared to PEN's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PEN's competition here
SRDX vs SWAV Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SRDX is priced at $42.98, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SRDX's ROE is -0.13%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SRDX is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SWAV's competition here
SRDX vs ALGN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, SRDX is priced at $42.98, while ALGN trades at $168.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ALGN's P/E ratio is 28.33. In terms of profitability, SRDX's ROE is -0.13%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ALGN's competition here
SRDX vs GMED Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, SRDX is priced at $42.98, while GMED trades at $80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GMED's P/E ratio is 18.69. In terms of profitability, SRDX's ROE is -0.13%, compared to GMED's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check GMED's competition here
SRDX vs PODD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, SRDX is priced at $42.98, while PODD trades at $146.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PODD's P/E ratio is 34.29. In terms of profitability, SRDX's ROE is -0.13%, compared to PODD's ROE of +0.21%. Regarding short-term risk, SRDX is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PODD's competition here
SRDX vs MASI Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, SRDX is priced at $42.98, while MASI trades at $178.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MASI's P/E ratio is 44.28. In terms of profitability, SRDX's ROE is -0.13%, compared to MASI's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to MASI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MASI's competition here
SRDX vs BRKR Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, SRDX is priced at $42.98, while BRKR trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKR's P/E ratio is -249.83. In terms of profitability, SRDX's ROE is -0.13%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, SRDX is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BRKR's competition here
SRDX vs BIO-B Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO-B has a market cap of 8.7B. Regarding current trading prices, SRDX is priced at $42.98, while BIO-B trades at $321.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO-B's P/E ratio is 53.40. In terms of profitability, SRDX's ROE is -0.13%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, SRDX is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BIO-B's competition here
SRDX vs BIO Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, SRDX is priced at $42.98, while BIO trades at $307.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO's P/E ratio is 51.06. In terms of profitability, SRDX's ROE is -0.13%, compared to BIO's ROE of +0.02%. Regarding short-term risk, SRDX is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BIO's competition here
SRDX vs GKOS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, SRDX is priced at $42.98, while GKOS trades at $121.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GKOS's P/E ratio is -36.87. In terms of profitability, SRDX's ROE is -0.13%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, SRDX is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check GKOS's competition here
SRDX vs NARI Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SRDX is priced at $42.98, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NARI's P/E ratio is -59.24. In terms of profitability, SRDX's ROE is -0.13%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NARI's competition here
SRDX vs LIVN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, SRDX is priced at $42.98, while LIVN trades at $73.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LIVN's P/E ratio is 37.61. In terms of profitability, SRDX's ROE is -0.13%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LIVN's competition here
SRDX vs AXNX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SRDX is priced at $42.98, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SRDX's ROE is -0.13%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SRDX and AXNX have similar daily volatility (0.00).Check AXNX's competition here
SRDX vs IRTC Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, SRDX is priced at $42.98, while IRTC trades at $107.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRTC's P/E ratio is -126.29. In terms of profitability, SRDX's ROE is -0.13%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, SRDX is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IRTC's competition here
SRDX vs ITGR Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, SRDX is priced at $42.98, while ITGR trades at $92.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ITGR's P/E ratio is 23.01. In terms of profitability, SRDX's ROE is -0.13%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, SRDX is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ITGR's competition here
SRDX vs TMDX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, SRDX is priced at $42.98, while TMDX trades at $71.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TMDX's P/E ratio is 16.33. In terms of profitability, SRDX's ROE is -0.13%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, SRDX is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TMDX's competition here
SRDX vs AXGN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, SRDX is priced at $42.98, while AXGN trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXGN's P/E ratio is -66.23. In terms of profitability, SRDX's ROE is -0.13%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, SRDX is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AXGN's competition here
SRDX vs ESTA Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, SRDX is priced at $42.98, while ESTA trades at $76.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ESTA's P/E ratio is -52.03. In terms of profitability, SRDX's ROE is -0.13%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, SRDX is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ESTA's competition here
SRDX vs NUVA Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SRDX is priced at $42.98, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SRDX's ROE is -0.13%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NUVA's competition here
SRDX vs UFPT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, SRDX is priced at $42.98, while UFPT trades at $224.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas UFPT's P/E ratio is 25.54. In terms of profitability, SRDX's ROE is -0.13%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, SRDX is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check UFPT's competition here
SRDX vs PRCT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, SRDX is priced at $42.98, while PRCT trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PRCT's P/E ratio is -14.75. In terms of profitability, SRDX's ROE is -0.13%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, SRDX is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PRCT's competition here
SRDX vs IART Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98, while IART trades at $17.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IART's P/E ratio is -2.71. In terms of profitability, SRDX's ROE is -0.13%, compared to IART's ROE of -0.48%. Regarding short-term risk, SRDX is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IART's competition here
SRDX vs BFLY Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98, while BFLY trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BFLY's P/E ratio is -17.30. In terms of profitability, SRDX's ROE is -0.13%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, SRDX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BFLY's competition here
SRDX vs TNDM Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while TNDM trades at $19.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TNDM's P/E ratio is -14.19. In terms of profitability, SRDX's ROE is -0.13%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, SRDX is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TNDM's competition here
SRDX vs AHCO Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while AHCO trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AHCO's P/E ratio is -16.47. In terms of profitability, SRDX's ROE is -0.13%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, SRDX is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AHCO's competition here
SRDX vs ENOV Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while ENOV trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ENOV's P/E ratio is -1.15. In terms of profitability, SRDX's ROE is -0.13%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, SRDX is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ENOV's competition here
SRDX vs HSKA Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SRDX's ROE is -0.13%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SRDX and HSKA have similar daily volatility (0.00).Check HSKA's competition here
SRDX vs ATEC Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, SRDX is priced at $42.98, while ATEC trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ATEC's P/E ratio is -9.54. In terms of profitability, SRDX's ROE is -0.13%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, SRDX is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ATEC's competition here
SRDX vs INSP Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, SRDX is priced at $42.98, while INSP trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INSP's P/E ratio is 9.58. In terms of profitability, SRDX's ROE is -0.13%, compared to INSP's ROE of +0.18%. Regarding short-term risk, SRDX is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INSP's competition here
SRDX vs IRMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, SRDX is priced at $42.98, while IRMD trades at $93.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRMD's P/E ratio is 51.13. In terms of profitability, SRDX's ROE is -0.13%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, SRDX is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IRMD's competition here
SRDX vs AVNS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, SRDX is priced at $42.98, while AVNS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVNS's P/E ratio is -15.62. In terms of profitability, SRDX's ROE is -0.13%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, SRDX is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AVNS's competition here
SRDX vs SILK Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SILK's P/E ratio is -18.96. In terms of profitability, SRDX's ROE is -0.13%, compared to SILK's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SILK's competition here
SRDX vs FNA Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas FNA's P/E ratio is -19.83. In terms of profitability, SRDX's ROE is -0.13%, compared to FNA's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check FNA's competition here
SRDX vs CNMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98, while CNMD trades at $35.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CNMD's P/E ratio is 19.84. In terms of profitability, SRDX's ROE is -0.13%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CNMD's competition here
SRDX vs AORT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AORT has a market cap of 1B. Regarding current trading prices, SRDX is priced at $42.98, while AORT trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AORT's P/E ratio is 83.32. In terms of profitability, SRDX's ROE is -0.13%, compared to AORT's ROE of +0.03%. Regarding short-term risk, SRDX is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AORT's competition here
SRDX vs CSII Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SRDX is priced at $42.98, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CSII's P/E ratio is -20.83. In terms of profitability, SRDX's ROE is -0.13%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SRDX is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CSII's competition here
SRDX vs INMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INMD has a market cap of 828.2M. Regarding current trading prices, SRDX is priced at $42.98, while INMD trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INMD's P/E ratio is 10.09. In terms of profitability, SRDX's ROE is -0.13%, compared to INMD's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INMD's competition here
SRDX vs LMRI Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LMRI has a market cap of 791.7M. Regarding current trading prices, SRDX is priced at $42.98, while LMRI trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LMRI's P/E ratio is -21.13. In terms of profitability, SRDX's ROE is -0.13%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, SRDX is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LMRI's competition here
SRDX vs SSII Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SSII has a market cap of 768.5M. Regarding current trading prices, SRDX is priced at $42.98, while SSII trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SSII's P/E ratio is -76.80. In terms of profitability, SRDX's ROE is -0.13%, compared to SSII's ROE of -0.23%. Regarding short-term risk, SRDX is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SSII's competition here
SRDX vs CRY Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, SRDX is priced at $42.98, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CRY's P/E ratio is 425.71. In terms of profitability, SRDX's ROE is -0.13%, compared to CRY's ROE of +0.03%. Regarding short-term risk, SRDX is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CRY's competition here
SRDX vs CBLL Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CBLL has a market cap of 711.4M. Regarding current trading prices, SRDX is priced at $42.98, while CBLL trades at $18.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CBLL's P/E ratio is -11.57. In terms of profitability, SRDX's ROE is -0.13%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, SRDX is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CBLL's competition here
SRDX vs SIBN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SIBN has a market cap of 659.9M. Regarding current trading prices, SRDX is priced at $42.98, while SIBN trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SIBN's P/E ratio is -38.15. In terms of profitability, SRDX's ROE is -0.13%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, SRDX is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SIBN's competition here
SRDX vs BVS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BVS has a market cap of 589.4M. Regarding current trading prices, SRDX is priced at $42.98, while BVS trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BVS's P/E ratio is 21.22. In terms of profitability, SRDX's ROE is -0.13%, compared to BVS's ROE of +0.16%. Regarding short-term risk, SRDX is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BVS's competition here
SRDX vs APEN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SRDX is priced at $42.98, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas APEN's P/E ratio is -9.43. In terms of profitability, SRDX's ROE is -0.13%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SRDX is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check APEN's competition here
SRDX vs TCMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TCMD has a market cap of 567.7M. Regarding current trading prices, SRDX is priced at $42.98, while TCMD trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TCMD's P/E ratio is 28.93. In terms of profitability, SRDX's ROE is -0.13%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TCMD's competition here
SRDX vs BWAY Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BWAY has a market cap of 559.7M. Regarding current trading prices, SRDX is priced at $42.98, while BWAY trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BWAY's P/E ratio is 64.86. In terms of profitability, SRDX's ROE is -0.13%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, SRDX is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BWAY's competition here
SRDX vs CTKB Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CTKB has a market cap of 559.2M. Regarding current trading prices, SRDX is priced at $42.98, while CTKB trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CTKB's P/E ratio is -7.47. In terms of profitability, SRDX's ROE is -0.13%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, SRDX is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CTKB's competition here
SRDX vs CERS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CERS has a market cap of 559M. Regarding current trading prices, SRDX is priced at $42.98, while CERS trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CERS's P/E ratio is -55.80. In terms of profitability, SRDX's ROE is -0.13%, compared to CERS's ROE of -0.15%. Regarding short-term risk, SRDX is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CERS's competition here
SRDX vs NPCE Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NPCE has a market cap of 556.4M. Regarding current trading prices, SRDX is priced at $42.98, while NPCE trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NPCE's P/E ratio is -25.11. In terms of profitability, SRDX's ROE is -0.13%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, SRDX is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NPCE's competition here
SRDX vs ZIMV Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SRDX is priced at $42.98, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SRDX's ROE is -0.13%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, SRDX and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here
SRDX vs PACB Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PACB has a market cap of 506.3M. Regarding current trading prices, SRDX is priced at $42.98, while PACB trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PACB's P/E ratio is -3.98. In terms of profitability, SRDX's ROE is -0.13%, compared to PACB's ROE of -4.88%. Regarding short-term risk, SRDX is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PACB's competition here
SRDX vs PMI Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PMI has a market cap of 498.9M. Regarding current trading prices, SRDX is priced at $42.98, while PMI trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PMI's P/E ratio is -0.42. In terms of profitability, SRDX's ROE is -0.13%, compared to PMI's ROE of +4.99%. Regarding short-term risk, SRDX is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PMI's competition here
SRDX vs LAB Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LAB has a market cap of 488M. Regarding current trading prices, SRDX is priced at $42.98, while LAB trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LAB's P/E ratio is -9.62. In terms of profitability, SRDX's ROE is -0.13%, compared to LAB's ROE of -0.21%. Regarding short-term risk, SRDX is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LAB's competition here
SRDX vs KIDS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, KIDS has a market cap of 464.9M. Regarding current trading prices, SRDX is priced at $42.98, while KIDS trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas KIDS's P/E ratio is -10.77. In terms of profitability, SRDX's ROE is -0.13%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, SRDX is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check KIDS's competition here
SRDX vs VREX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, VREX has a market cap of 440.4M. Regarding current trading prices, SRDX is priced at $42.98, while VREX trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas VREX's P/E ratio is -5.23. In terms of profitability, SRDX's ROE is -0.13%, compared to VREX's ROE of -0.18%. Regarding short-term risk, SRDX is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check VREX's competition here
SRDX vs CLPT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CLPT has a market cap of 429.5M. Regarding current trading prices, SRDX is priced at $42.98, while CLPT trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CLPT's P/E ratio is -14.32. In terms of profitability, SRDX's ROE is -0.13%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, SRDX is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CLPT's competition here
SRDX vs OFIX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, OFIX has a market cap of 416.7M. Regarding current trading prices, SRDX is priced at $42.98, while OFIX trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas OFIX's P/E ratio is -6.87. In terms of profitability, SRDX's ROE is -0.13%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check OFIX's competition here
SRDX vs VMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, SRDX is priced at $42.98, while VMD trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas VMD's P/E ratio is 26.59. In terms of profitability, SRDX's ROE is -0.13%, compared to VMD's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check VMD's competition here
SRDX vs DCTH Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DCTH has a market cap of 372.5M. Regarding current trading prices, SRDX is priced at $42.98, while DCTH trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DCTH's P/E ratio is 1079.00. In terms of profitability, SRDX's ROE is -0.13%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, SRDX is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check DCTH's competition here
SRDX vs AVR Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVR has a market cap of 355M. Regarding current trading prices, SRDX is priced at $42.98, while AVR trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVR's P/E ratio is -4.35. In terms of profitability, SRDX's ROE is -0.13%, compared to AVR's ROE of -1.24%. Regarding short-term risk, SRDX is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AVR's competition here
SRDX vs ICCM Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ICCM has a market cap of 347.8M. Regarding current trading prices, SRDX is priced at $42.98, while ICCM trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ICCM's P/E ratio is -21.54. In terms of profitability, SRDX's ROE is -0.13%, compared to ICCM's ROE of -2.12%. Regarding short-term risk, SRDX is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ICCM's competition here
SRDX vs MASS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MASS has a market cap of 333.5M. Regarding current trading prices, SRDX is priced at $42.98, while MASS trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MASS's P/E ratio is -9.09. In terms of profitability, SRDX's ROE is -0.13%, compared to MASS's ROE of -0.26%. Regarding short-term risk, SRDX is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MASS's competition here
SRDX vs SMLR Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SRDX is priced at $42.98, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SRDX's ROE is -0.13%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, SRDX and SMLR have similar daily volatility (0.00).Check SMLR's competition here
SRDX vs ELMD Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, SRDX is priced at $42.98, while ELMD trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ELMD's P/E ratio is 31.51. In terms of profitability, SRDX's ROE is -0.13%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, SRDX is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ELMD's competition here
SRDX vs SENS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SENS has a market cap of 292.8M. Regarding current trading prices, SRDX is priced at $42.98, while SENS trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SENS's P/E ratio is -3.56. In terms of profitability, SRDX's ROE is -0.13%, compared to SENS's ROE of -1.30%. Regarding short-term risk, SRDX is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SENS's competition here
SRDX vs CATX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CATX has a market cap of 250.3M. Regarding current trading prices, SRDX is priced at $42.98, while CATX trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CATX's P/E ratio is -2.30. In terms of profitability, SRDX's ROE is -0.13%, compared to CATX's ROE of -0.42%. Regarding short-term risk, SRDX is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CATX's competition here
SRDX vs SGHT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SGHT has a market cap of 250.3M. Regarding current trading prices, SRDX is priced at $42.98, while SGHT trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SGHT's P/E ratio is -6.57. In terms of profitability, SRDX's ROE is -0.13%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, SRDX is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SGHT's competition here
SRDX vs MGRM Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SRDX is priced at $42.98, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MGRM's P/E ratio is -11.11. In terms of profitability, SRDX's ROE is -0.13%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, SRDX and MGRM have similar daily volatility (0.00).Check MGRM's competition here
SRDX vs TMCI Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TMCI has a market cap of 239.4M. Regarding current trading prices, SRDX is priced at $42.98, while TMCI trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TMCI's P/E ratio is -3.84. In terms of profitability, SRDX's ROE is -0.13%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, SRDX is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TMCI's competition here
SRDX vs NVRO Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SRDX is priced at $42.98, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SRDX's ROE is -0.13%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SRDX is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NVRO's competition here
SRDX vs RXST Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, SRDX is priced at $42.98, while RXST trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RXST's P/E ratio is -4.51. In terms of profitability, SRDX's ROE is -0.13%, compared to RXST's ROE of -0.17%. Regarding short-term risk, SRDX is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check RXST's competition here
SRDX vs EYES Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, SRDX is priced at $42.98, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EYES's P/E ratio is N/A. In terms of profitability, SRDX's ROE is -0.13%, compared to EYES's ROE of -2.64%. Regarding short-term risk, SRDX is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EYES's competition here
SRDX vs PROF Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PROF has a market cap of 205.8M. Regarding current trading prices, SRDX is priced at $42.98, while PROF trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PROF's P/E ratio is -5.48. In terms of profitability, SRDX's ROE is -0.13%, compared to PROF's ROE of -0.71%. Regarding short-term risk, SRDX is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PROF's competition here
SRDX vs ANIK Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ANIK has a market cap of 196.8M. Regarding current trading prices, SRDX is priced at $42.98, while ANIK trades at $14.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ANIK's P/E ratio is -18.72. In terms of profitability, SRDX's ROE is -0.13%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, SRDX is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ANIK's competition here
SRDX vs BSGM Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SRDX is priced at $42.98, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SRDX's ROE is -0.13%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, SRDX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSGM's competition here
SRDX vs APYX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, APYX has a market cap of 179.6M. Regarding current trading prices, SRDX is priced at $42.98, while APYX trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas APYX's P/E ratio is -19.50. In terms of profitability, SRDX's ROE is -0.13%, compared to APYX's ROE of -0.91%. Regarding short-term risk, SRDX is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check APYX's competition here
SRDX vs QTRX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QTRX has a market cap of 179M. Regarding current trading prices, SRDX is priced at $42.98, while QTRX trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QTRX's P/E ratio is -1.62. In terms of profitability, SRDX's ROE is -0.13%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check QTRX's competition here
SRDX vs MDGS Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SRDX is priced at $42.98, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SRDX's ROE is -0.13%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SRDX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MDGS's competition here
SRDX vs EDAP Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, SRDX is priced at $42.98, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EDAP's P/E ratio is -5.80. In terms of profitability, SRDX's ROE is -0.13%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, SRDX is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EDAP's competition here
SRDX vs INGN Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INGN has a market cap of 170.8M. Regarding current trading prices, SRDX is priced at $42.98, while INGN trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INGN's P/E ratio is -6.93. In terms of profitability, SRDX's ROE is -0.13%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INGN's competition here
SRDX vs QIPT Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, SRDX is priced at $42.98, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QIPT's P/E ratio is -15.87. In terms of profitability, SRDX's ROE is -0.13%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SRDX and QIPT have similar daily volatility (0.00).Check QIPT's competition here
SRDX vs CVRX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CVRX has a market cap of 156M. Regarding current trading prices, SRDX is priced at $42.98, while CVRX trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CVRX's P/E ratio is -2.93. In terms of profitability, SRDX's ROE is -0.13%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, SRDX is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CVRX's competition here
SRDX vs NNOX Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NNOX has a market cap of 144.1M. Regarding current trading prices, SRDX is priced at $42.98, while NNOX trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NNOX's P/E ratio is -1.78. In terms of profitability, SRDX's ROE is -0.13%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, SRDX is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NNOX's competition here
SRDX vs SNWV Comparison June 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SNWV has a market cap of 135M. Regarding current trading prices, SRDX is priced at $42.98, while SNWV trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SNWV's P/E ratio is 16.35. In terms of profitability, SRDX's ROE is -0.13%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, SRDX is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SNWV's competition here